To study the clinical variations and dose volume changes with adaptive radiotherapy in head and neck cancers
Not Applicable
Completed
- Conditions
- Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
- Registration Number
- CTRI/2021/09/036417
- Lead Sponsor
- svims tirupati
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 64
Inclusion Criteria
1. histopathologically proven squamous cell carcinoma of head and neck
2.cancers of oralcavity, oropharynx, hypopharynx and larynx
3. stage 3 to stage 4b disease
4. patients with ECOG performance status 0 to 2
5. patients who has given approved informed consent
Exclusion Criteria
1. patients previously treated with surgery, chemotherapy or radiotherapy
2. patients with distant metastasis
3.patients with ECOG performance status 3 and 4
4.pregnant women and lactating mothers
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AIM <br/ ><br>To evaluate clinical outcome variations and dose volumetric changes with adaptive IMRT in head and neck cancers <br/ ><br> <br/ ><br>objectives <br/ ><br>to document and assess following parameters <br/ ><br>1. acute toxicities <br/ ><br>a) mucositis <br/ ><br>b) dermatitis <br/ ><br>c) dysphagia <br/ ><br>d) voice changes <br/ ><br>e) xerostomia <br/ ><br>2. clinical responce rate <br/ ><br>a) changes in gross tumor volume (GTV) <br/ ><br>b) changes in nodal volume <br/ ><br>3. Dose volumetric parameters <br/ ><br>a) dose to parotid gland <br/ ><br>b) dose to spinal cordTimepoint: all the patients will undergo CT simulation and treatment planning by IMRT <br/ ><br>patients will be assessed baseline and weekly basis during RT for acute toxicities <br/ ><br>patients will undergo rescan and replanning around 23fractions (3 to 5 weeks) and dose volume changes are compared with inital scan
- Secondary Outcome Measures
Name Time Method